{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:49:45Z","timestamp":1772552985797,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"unspecified","delay-in-days":133,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shandong Provincial Key R&D Program","award":["2017G006021"],"award-info":[{"award-number":["2017G006021"]}]},{"name":"Zhejiang Medical Health Technology Project","award":["2023KY613"],"award-info":[{"award-number":["2023KY613"]}]},{"name":"Zhejiang Traditional Chinese Medicine Research Program","award":["2023ZL281"],"award-info":[{"award-number":["2023ZL281"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81303013"],"award-info":[{"award-number":["81303013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,10,12]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>This article has been retracted.<\/jats:p>","DOI":"10.1136\/bmjno-2025-001249","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:10:33Z","timestamp":1762884633000},"page":"e001249","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the therapeutic potential of IL-17A inhibition in myasthenia gravis: a retrospective study on secukinumab"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6392-1267","authenticated-orcid":false,"given":"Zhaoxu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7481-6334","authenticated-orcid":false,"given":"Shuang Mei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pain Rehabilitation, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China"},{"name":"Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-4751","authenticated-orcid":false,"given":"Anrong","family":"Wang","sequence":"additional","affiliation":[{"name":"Shandong Provincial Qianfoshan Hospital, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3974-1693","authenticated-orcid":false,"given":"Pingbo","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pain Rehabilitation, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China"},{"name":"Chinese Academy of Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"2025111110102749000_7.2.e001249.1","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J Clin Invest"},{"key":"2025111110102749000_7.2.e001249.2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/WCO.0000000000001196","article-title":"Current drug treatment of myasthenia gravis","volume":"36","author":"Vanoli","year":"2023","journal-title":"Curr Opin Neurol"},{"key":"2025111110102749000_7.2.e001249.3","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00981","article-title":"From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research","volume":"11","author":"Mantegazza","year":"2020","journal-title":"Front Neurol"},{"key":"2025111110102749000_7.2.e001249.4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14737175.2023.2207739","article-title":"Conventional and emerging treatments and controversies in myasthenia gravis","volume":"23","author":"Evoli","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"2025111110102749000_7.2.e001249.5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1280029","article-title":"Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"2025111110102749000_7.2.e001249.6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00809","article-title":"CD4+ T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS","volume":"11","author":"\u00c7ebi","year":"2020","journal-title":"Front Immunol"},{"key":"2025111110102749000_7.2.e001249.7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.molimm.2021.02.011","article-title":"Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis","volume":"133","author":"Chen","year":"2021","journal-title":"Mol Immunol"},{"key":"2025111110102749000_7.2.e001249.8","doi-asserted-by":"crossref","first-page":"108492","DOI":"10.1016\/j.clim.2020.108492","article-title":"Circulating Th1\/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients","volume":"218","author":"Ma","year":"2020","journal-title":"Clin Immunol"},{"key":"2025111110102749000_7.2.e001249.9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11481-021-10030-7","article-title":"Increased Expression of CD95 in CD4+ Effector Memory T Cells Promotes Th17 Response in Patients with Myasthenia Gravis","volume":"17","author":"Huang","year":"2022","journal-title":"J Neuroimmune Pharmacol"},{"key":"2025111110102749000_7.2.e001249.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26030","article-title":"Curcumin protects mice with myasthenia gravis by regulating the gut microbiota, short-chain fatty acids, and the Th17\/Treg balance","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"2025111110102749000_7.2.e001249.11","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13546"},{"key":"2025111110102749000_7.2.e001249.12","doi-asserted-by":"crossref","first-page":"103826","DOI":"10.1016\/j.autrev.2025.103826","article-title":"Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab","volume":"24","author":"Li","year":"2025","journal-title":"Autoimmun Rev"},{"key":"2025111110102749000_7.2.e001249.13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12026-020-09164-2","article-title":"IL-21 enhances STAT3\/Blimp-1 signaling pathway in B cells and contributes to plasma cell differentiation in newly diagnosed patients with myasthenia gravis","volume":"69","author":"Xu","year":"2021","journal-title":"Immunol Res"},{"key":"2025111110102749000_7.2.e001249.14","doi-asserted-by":"crossref","first-page":"108830","DOI":"10.1016\/j.clim.2021.108830","article-title":"Cellular changes in eculizumab early responders with generalized myasthenia gravis","volume":"231","author":"Li","year":"2021","journal-title":"Clin Immunol"},{"key":"2025111110102749000_7.2.e001249.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"2025111110102749000_7.2.e001249.16","doi-asserted-by":"crossref","first-page":"8287","DOI":"10.1007\/s00210-025-03954-x","article-title":"A systematic review of efgartigimod as an effective treatment for myasthenic crisis","volume":"398","author":"Tang","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2025111110102749000_7.2.e001249.17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218011","article-title":"CD4 T Helper Cell Subsets and Related Human Immunological Disorders","volume":"21","author":"Zhu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025111110102749000_7.2.e001249.18","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur J Immunol"},{"key":"2025111110102749000_7.2.e001249.19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neurol.2024.09.006","article-title":"New treatment strategies in Myasthenia gravis","volume":"180","author":"Attarian","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"2025111110102749000_7.2.e001249.20","first-page":"1637","article-title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regen Res"},{"key":"2025111110102749000_7.2.e001249.21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14712598.2023.2184257","article-title":"Biological therapies for myasthenia gravis","volume":"23","author":"Uzawa","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2025111110102749000_7.2.e001249.22","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.3390\/ijms22115755","article-title":"Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis","volume":"22","author":"Keller","year":"2021","journal-title":"IJMS"},{"key":"2025111110102749000_7.2.e001249.23","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2025111110102749000_7.2.e001249.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1149629","article-title":"Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab","volume":"14","author":"Nytrova","year":"2023","journal-title":"Front Immunol"},{"key":"2025111110102749000_7.2.e001249.25","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2082946"},{"key":"2025111110102749000_7.2.e001249.26","doi-asserted-by":"crossref","first-page":"109141","DOI":"10.1016\/j.clim.2022.109141","article-title":"Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells","volume":"245","author":"Li","year":"2022","journal-title":"Clin Immunol"},{"key":"2025111110102749000_7.2.e001249.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e23745","article-title":"Altered serum levels of cytokines in patients with myasthenia gravis","volume":"10","author":"Wei","year":"2024","journal-title":"Heliyon"},{"key":"2025111110102749000_7.2.e001249.28","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-025-01603-4","article-title":"Phenotypic and functional dysregulations of CD8\u2009+\u2009T Cells in myasthenia gravis","volume":"25","author":"Liu","year":"2025","journal-title":"Clin Exp Med"},{"key":"2025111110102749000_7.2.e001249.29","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9"},{"key":"2025111110102749000_7.2.e001249.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"}],"updated-by":[{"DOI":"10.1136\/bmjno-2025-001249ret","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000}}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:10:29Z","timestamp":1772518229000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,11]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjno-2025-001249"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001249","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}